Virbac announces the signature of a definitive agreement with ORIX Corporation for the acquisition of its animal health subsidiary Sasaeah for an enterprise value of around 280 million euros, a transaction which gives the French company a leading position in Japan.

Sasaeah develops, manufactures and markets a broad portfolio of veterinary products for livestock and companion animals. It generates annual revenues of around €75 million, 50% of which come from vaccines, and has over 500 employees.

This transaction, which should be finalized in early April, will give Virbac a leading position in farm animal vaccines in Japan, particularly for cattle, and a broad portfolio of pharmaceutical products for all the main species.

Copyright (c) 2024 CercleFinance.com. All rights reserved.